8-K Announcements
6Material company update
Mar 11, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Jan 12, 2026·SEC
Foghorn Therapeutics Inc.(FHTX)Earnings, Financials & Key Ratios
FHTX•NASDAQ
$4.20
$238M mkt cap·Price updated May 7, 2026
AboutFoghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$31M+36.8%
- EBITDA-$79M+20.9%
- Net Income-$74M+14.2%
- EPS (Diluted)-1.18+25.3%
- Gross Margin89.22%-10.8%
- EBITDA Margin-254.86%+42.1%
- Operating Margin-265.64%+41.5%
- Net Margin-240.33%+37.3%
FHTX Key Insights
Foghorn Therapeutics Inc. (FHTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 135.1%
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 14.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FHTX Price & Volume
Foghorn Therapeutics Inc. (FHTX) stock price & volume — 10-year historical chart
Loading chart...
FHTX Growth Metrics
Foghorn Therapeutics Inc. (FHTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years135.14%
3 Years17.14%
TTM36.75%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.92%
Return on Capital
10 Years-64.44%
5 Years-37.36%
3 Years-43.27%
Last Year-46.21%
FHTX Recent Earnings
Foghorn Therapeutics Inc. (FHTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
Mar 11, 2026EPS
$0.34
Est $0.28
-21.4%
Revenue
$9M
Est $10M
-8.9%
Q4 2025
Nov 5, 2025EPS
$0.25
Est $0.31
+19.4%
Revenue
$8M
Est $9M
-14.2%
Q3 2025
Aug 5, 2025EPS
$0.28
Est $0.31
+9.7%
Revenue
$8M
Est $8M
-7.5%
Q2 2025
May 14, 2025EPS
$0.30
Est $0.30
+0.0%
Revenue
$6M
Est $6M
-4.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 11, 2026 | $0.34vs $0.28-21.4% | $9Mvs $10M-8.9% |
| Q4 2025 | Nov 5, 2025 | $0.25vs $0.31+19.4% | $8Mvs $9M-14.2% |
| Q3 2025 | Aug 5, 2025 | $0.28vs $0.31+9.7% | $8Mvs $8M-7.5% |
| Q2 2025 | May 14, 2025 | $0.30vs $0.30+0.0% | $6Mvs $6M-4.6% |
Based on last 12 quarters of dataView full earnings history →
FHTX Peer Comparison
Foghorn Therapeutics Inc. (FHTX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RVMD | 30.3B | 142.51 | -23.95 | -83.22% | 0.10 | |||
 TNGX | 3.19B | 23.48 | -26.99 | 48.29% | -162.85% | -50.3% | 0.10 | |
 VYNE | 28.8M | 0.67 | -1.09 | 13.77% | -46.46% | -74.15% | ||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 AUPH | 2B | 15.14 | 7.31 | 20.38% | 101.47% | 49.4% | 0.13 | |
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARQT | 2.58B | 20.66 | -158.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 |
Compare FHTX vs Peers
Foghorn Therapeutics Inc. (FHTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FHTX Income Statement
Foghorn Therapeutics Inc. (FHTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 430K | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Revenue Growth % | - | - | - | 206.74% | 1357.77% | 77.63% | -33.83% | 36.75% |
| Cost of Goods Sold | 379K | 1.79M | 57.72M | 0 | 0 | 0 | 0 | 3.33M |
| COGS % of Revenue | - | - | 13422.09% | - | - | - | - | 10.78% |
| Gross Profit | -379K▲ 0% | -1.79M▼ 373.1% | -57.28M▼ 3094.9% | 1.32M▲ 102.3% | 19.23M▲ 1357.8% | 34.16M▲ 77.6% | 22.6M▼ 33.8% | 27.58M▲ 22.0% |
| Gross Margin % | - | - | -13322.09% | 100% | 100% | 100% | 100% | 89.22% |
| Gross Profit Growth % | - | -373.09% | -3094.92% | 102.3% | 1357.77% | 77.63% | -33.83% | 22.01% |
| Operating Expenses | 26.05M | 49.29M | 11.25M | 102.05M | 136.37M | 142.06M | 125.28M | 109.68M |
| OpEx % of Revenue | - | - | 2615.35% | 7737.15% | 709.2% | 415.93% | 554.31% | 354.86% |
| Selling, General & Admin | 4.82M | 4.93M | 11.25M | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| SG&A % of Revenue | - | - | 2615.35% | 1647.31% | 159.91% | 94.78% | 125.47% | 89.13% |
| Research & Development | 21.23M | 44.36M | 57.72M | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| R&D % of Revenue | - | - | 13422.09% | 6089.84% | 549.29% | 321.15% | 418.23% | 276.51% |
| Other Operating Expenses | 0 | 0 | -57.72M | 0 | 0 | 0 | 2.4M | -3.33M |
| Operating Income | -26.05M▲ 0% | -51.08M▼ 96.1% | -68.53M▼ 34.2% | -100.73M▼ 47.0% | -117.14M▼ 16.3% | -107.91M▲ 7.9% | -102.68M▲ 4.8% | -82.11M▲ 20.0% |
| Operating Margin % | - | - | -15937.44% | -7637.15% | -609.2% | -315.93% | -454.31% | -265.64% |
| Operating Income Growth % | - | -96.11% | -34.15% | -46.99% | -16.28% | 7.88% | 4.84% | 20.04% |
| EBITDA | -25.67M | -49.29M | -67.2M | -97.51M | -113.82M | -104.45M | -99.56M | -78.78M |
| EBITDA Margin % | - | - | -15628.84% | -7392.49% | -591.93% | -305.83% | -440.51% | -254.86% |
| EBITDA Growth % | - | -92.02% | -36.34% | -45.09% | -16.73% | 8.22% | 4.68% | 20.88% |
| D&A (Non-Cash Add-back) | 379K | 1.79M | 1.33M | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBIT | -25.97M | -50.59M | -68.53M | -99.41M | -117.14M | -107.91M | -100.28M | -82.11M |
| Net Interest Income | -258K | -45K | 22K | -1.85M | 5.67M | 10.88M | 11.9M | 8.74M |
| Interest Income | 113K | 495K | 1M | 59K | 5.67M | 10.88M | 11.9M | 8.74M |
| Interest Expense | 371K | 540K | 979K | 1.91M | 0 | 0 | 0 | 0 |
| Other Income/Expense | -288K | -44K | -269K | -586K | 8.26M | 13.71M | 16.06M | 7.82M |
| Pretax Income | -26.34M▲ 0% | -51.13M▼ 94.1% | -68.8M▼ 34.6% | -101.32M▼ 47.3% | -108.88M▼ 7.5% | -94.2M▲ 13.5% | -86.62M▲ 8.0% | -74.28M▲ 14.2% |
| Pretax Margin % | - | - | -16000% | -7681.58% | -566.27% | -275.8% | -383.24% | -240.33% |
| Income Tax | 83K | 0 | 0 | 0 | 0 | 4.23M | 0 | 0 |
| Effective Tax Rate % | -0.32% | 0% | 0% | 0% | 0% | -4.49% | 0% | 0% |
| Net Income | -26.34M▲ 0% | -51.13M▼ 94.1% | -68.8M▼ 34.6% | -101.32M▼ 47.3% | -108.88M▼ 7.5% | -98.43M▲ 9.6% | -86.62M▲ 12.0% | -74.28M▲ 14.2% |
| Net Margin % | - | - | -16000% | -7681.58% | -566.27% | -288.17% | -383.24% | -240.33% |
| Net Income Growth % | - | -94.13% | -34.56% | -47.27% | -7.46% | 9.6% | 11.99% | 14.24% |
| Net Income (Continuing) | -26.34M | -51.13M | -68.8M | -101.32M | -108.88M | -98.43M | -86.62M | -74.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.34▲ 0% | -1.40▼ 4.5% | -1.90▼ 35.7% | -2.78▼ 46.3% | -2.62▲ 5.8% | -2.34▲ 10.7% | -1.58▲ 32.5% | -1.18▲ 25.3% |
| EPS Growth % | - | -4.48% | -35.71% | -46.32% | 5.76% | 10.69% | 32.48% | 25.32% |
| EPS (Basic) | -1.34 | -1.40 | -1.90 | -2.78 | -2.62 | -2.34 | -1.58 | -1.18 |
| Diluted Shares Outstanding | 19.63M | 36.82M | 36.79M | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Basic Shares Outstanding | 19.63M | 36.82M | 36.79M | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
FHTX Balance Sheet
Foghorn Therapeutics Inc. (FHTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 40.4M | 16.89M | 190.69M | 459.56M | 351.4M | 240.18M | 249.6M | 163.24M |
| Cash & Short-Term Investments | 40.02M | 14.98M | 185.77M | 154.29M | 345.8M | 234.06M | 243.75M | 158.89M |
| Cash Only | 40.02M | 14.98M | 92.8M | 101.14M | 52.21M | 80.34M | 55.45M | 80.88M |
| Short-Term Investments | 0 | 0 | 92.97M | 53.15M | 293.58M | 153.72M | 188.29M | 78.02M |
| Accounts Receivable | 0 | 0 | 0 | 300M | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | 83.02K | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 541K | 0 | 0 | 5.6M | 6.12M | 5.85M | 4.34M |
| Total Non-Current Assets | 2.66M | 5.46M | 64.91M | 60.21M | 53.48M | 45.73M | 34.38M | 34.87M |
| Property, Plant & Equipment | 2.09M | 3.71M | 62.33M | 56.08M | 49.4M | 42.91M | 32.6M | 32.86M |
| Fixed Asset Turnover | - | - | 0.01x | 0.02x | 0.39x | 0.80x | 0.69x | 0.94x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 566K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 1.74M | 2.58M | 4.13M | 4.09M | 2.82M | 1.78M | 2M |
| Total Assets | 43.06M▲ 0% | 22.34M▼ 48.1% | 255.59M▲ 1044.0% | 519.77M▲ 103.4% | 404.88M▼ 22.1% | 285.92M▼ 29.4% | 283.98M▼ 0.7% | 198.1M▼ 30.2% |
| Asset Turnover | - | - | 0.00x | 0.00x | 0.05x | 0.12x | 0.08x | 0.16x |
| Asset Growth % | - | -48.11% | 1044.01% | 103.36% | -22.1% | -29.38% | -0.68% | -30.24% |
| Total Current Liabilities | 3.46M | 12.65M | 18.85M | 48.69M | 55.2M | 58.44M | 66.99M | 59.74M |
| Accounts Payable | 2.01M | 3.44M | 3.68M | 3.82M | 5.41M | 6.26M | 3.79M | 4.27M |
| Days Payables Outstanding | 1.94K | 700.08 | 23.27 | - | - | - | - | 467.31 |
| Short-Term Debt | 0 | 4.15M | 0 | 0 | 0 | 0 | 0 | 923K |
| Deferred Revenue (Current) | 0 | 0 | 2.02M | 28.32M | 32.82M | 34.55M | 45.61M | 43.19M |
| Other Current Liabilities | 0 | 1.92M | 3.65M | 5.99M | 5.06M | 4.38M | 4.74M | 11.36M |
| Current Ratio | 11.68x | 1.33x | 10.12x | 9.44x | 6.37x | 4.11x | 3.73x | 2.73x |
| Quick Ratio | 11.68x | 1.33x | 10.12x | 9.44x | 6.37x | 4.11x | 3.73x | 2.73x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 78.87M | 97.71M | 90.56M | 374.21M | 349.57M | 304.67M | 262.52M | 246.87M |
| Long-Term Debt | 7.03M | 10.96M | 19.65M | 0 | 0 | 0 | 0 | 40.35M |
| Capital Lease Obligations | 0 | 157K | 58.36M | 51.34M | 45.54M | 36.55M | 28.06M | 40.35M |
| Deferred Tax Liabilities | -547K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 71.84M | 86.59M | 0 | 143K | 29K | 0 | 0 | 556K |
| Total Liabilities | 82.33M | 110.36M | 109.41M | 422.9M | 404.77M | 363.11M | 329.51M | 306.6M |
| Total Debt | 7.03M | 16.63M | 82M | 58.33M | 51.51M | 45.07M | 37.13M | 41.27M |
| Net Debt | -32.99M | 1.65M | -10.8M | -42.8M | -707K | -35.26M | -18.32M | -39.61M |
| Debt / Equity | - | - | 0.56x | 0.60x | 459.88x | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -70.21x | -94.60x | -70.00x | -52.85x | - | - | - | - |
| Total Equity | -39.27M▲ 0% | -88.02M▼ 124.1% | 146.19M▲ 266.1% | 96.87M▼ 33.7% | 112K▼ 99.9% | -77.19M▼ 69019.6% | -45.53M▲ 41.0% | -108.5M▼ 138.3% |
| Equity Growth % | - | -124.11% | 266.09% | -33.73% | -99.88% | -69019.64% | 41.02% | -138.31% |
| Book Value per Share | -2.00 | -2.39 | 3.97 | 2.61 | 0.00 | -1.84 | -0.83 | -1.72 |
| Total Shareholders' Equity | -39.27M | -88.02M | 146.19M | 96.87M | 112K | -77.19M | -45.53M | -108.5M |
| Common Stock | 1K | 0 | 4K | 4K | 4K | 4K | 6K | 6K |
| Retained Earnings | -43.01M | -94.14M | -162.94M | -264.26M | -373.14M | -471.56M | -558.18M | -632.47M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -616K | 0 | -7K | -10K | -3.99M | -826K | 135K | 24K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FHTX Cash Flow Statement
Foghorn Therapeutics Inc. (FHTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -22.65M | -46.34M | -31.29M | -50.25M | 193.61M | -118.11M | -100.41M | -86.1M |
| Operating CF Margin % | - | - | -7275.81% | -3809.7% | 1006.93% | -345.79% | -444.24% | -278.56% |
| Operating CF Growth % | - | -104.59% | 32.48% | -60.61% | 485.3% | -161% | 14.99% | 14.25% |
| Net Income | -26.34M | -51.13M | -68.8M | -101.32M | -108.88M | -98.43M | -86.62M | -74.28M |
| Depreciation & Amortization | 379K | 693K | 1.33M | 3.23M | 7.9M | 3.45M | 3.12M | 3.33M |
| Stock-Based Compensation | 732K | 1.69M | 2.96M | 8.38M | 0 | 16.19M | 11.89M | 10.4M |
| Deferred Taxes | 30K | 0 | 84K | 1.41M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 124K | 1.21M | 4.44M | 4.61M | 13.05M | 2.56M | 3.47M | 6.59M |
| Working Capital Changes | 2.42M | 1.2M | 28.7M | 33.44M | 281.55M | -41.88M | -32.27M | -32.14M |
| Change in Receivables | 0 | 0 | 0 | -300M | 300M | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | -3.17M | 0 | 0 | 0 | 0 |
| Change in Payables | 1.28M | 1.21M | 474K | 135K | 1.61M | 846K | -2.48M | 481K |
| Cash from Investing | -1.54M | -964K | -108.91M | 36.17M | -244.32M | 144.45M | -29.9M | 112.04M |
| Capital Expenditures | -1.54M | -968K | -16.18M | -3.31M | -1.21M | -1.22M | -906K | -50K |
| CapEx % of Revenue | - | - | 3763.49% | 251.18% | 6.29% | 3.58% | 4.01% | 0.16% |
| Acquisitions | 0 | 0 | 250K | -39.49M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 4K | 250K | 39.49M | 0 | 0 | 0 | 0 |
| Cash from Financing | 51.77M | 23.97M | 217.47M | 22.42M | 1.76M | 1.78M | 105.43M | 1.02M |
| Debt Issued (Net) | 11.14M | 7.98M | 4.27M | -21.2M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 190K | 691K | 1.22M | 1.42M | 0 | 1.78M | 2.03M | 0 |
| Net Change in Cash | 27.58M▲ 0% | -23.33M▼ 184.6% | 77.27M▲ 431.2% | 8.34M▼ 89.2% | -48.92M▼ 686.5% | 28.12M▲ 157.5% | -24.88M▼ 188.5% | 26.96M▲ 208.4% |
| Free Cash Flow | -24.19M▲ 0% | -47.3M▼ 95.6% | -47.47M▼ 0.4% | -53.56M▼ 12.8% | 192.4M▲ 459.2% | -119.33M▼ 162.0% | -101.31M▲ 15.1% | -86.15M▲ 15.0% |
| FCF Margin % | - | - | -11039.3% | -4060.88% | 1000.63% | -349.38% | -448.24% | -278.72% |
| FCF Growth % | - | -95.56% | -0.35% | -12.84% | 459.21% | -162.02% | 15.1% | 14.97% |
| FCF per Share | -1.23 | -1.28 | -1.29 | -1.44 | 4.63 | -2.84 | -1.85 | -1.37 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.91x | 0.45x | 0.50x | -1.78x | 1.20x | 1.16x | 1.16x |
| Interest Paid | 0 | 420K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 3.55M | 860K | 0 |
FHTX Key Ratios
Foghorn Therapeutics Inc. (FHTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -236.54% | -83.37% | -224.54% | - | - | - |
| Return on Invested Capital (ROIC) | - | - | -209.7% | -79.76% | -328.59% | - | - | - |
| Gross Margin | - | - | -13322.09% | 100% | 100% | 100% | 100% | 89.22% |
| Net Margin | - | - | -16000% | -7681.58% | -566.27% | -288.17% | -383.24% | -240.33% |
| Debt / Equity | - | - | 0.56x | 0.60x | 459.88x | - | - | - |
| Interest Coverage | -70.21x | -94.60x | -70.00x | -52.85x | - | - | - | - |
| FCF Conversion | 0.86x | 0.91x | 0.45x | 0.50x | -1.78x | 1.20x | 1.16x | 1.16x |
| Revenue Growth | - | - | - | 206.74% | 1357.77% | 77.63% | -33.83% | 36.75% |
FHTX SEC Filings & Documents
Foghorn Therapeutics Inc. (FHTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
FHTX Frequently Asked Questions
Foghorn Therapeutics Inc. (FHTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Foghorn Therapeutics Inc. (FHTX) reported $30.9M in revenue for fiscal year 2025.
Foghorn Therapeutics Inc. (FHTX) grew revenue by 36.8% over the past year. This is strong growth.
Foghorn Therapeutics Inc. (FHTX) reported a net loss of $74.3M for fiscal year 2025.
Dividend & Returns
Foghorn Therapeutics Inc. (FHTX) had negative free cash flow of $86.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More FHTX
Foghorn Therapeutics Inc. (FHTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates